Imaging extracellular vesicles: current and emerging methods.

Chuo ST, Chien JC, Lai CP. · 2018

Read Imaging extracellular vesicles: current and emerging methods. by Chuo ST, Chien JC, Lai CP. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6304785.txt.

Introduction

Chuo and co-authors review ways to image extracellular vesicles. The review appeared in the Journal of Biomedical Science. Vesicles are tiny sacs that cells release. They carry proteins, lipids, and RNA between cells. They play roles in development and in cancer. Their nanometer size makes them hard to picture.

The authors survey current labeling and imaging strategies. Each method has strengths and trade-offs. A wrong label choice can distort what researchers see. The review also covers newer emerging tools. It explains how vesicles move in space and time. Readers gain a guide to picking a method. That helps future vesicle studies stay accurate.

Catalog record

CREATORChuo ST, Chien JC, Lai CP.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE51 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6304785

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Imaging extracellular vesicles: current and emerging methods By Steven Ting-Yu Chuo, Jasper Che-Yung Chien, Charles Pin-Kuang Lai Published in: Journal of Biomedical Science DOI: 10.1186/s12929-018-0494-5 ABSTRACT Extracellular vesicles (EVs) are lipid bilayer-enclosed nanoparticles released by cells. They range from 30 nm to several micrometers in diameter, and ferry biological cargos such as proteins, lipids, RNAs and DNAs for local and distant intercellular communications. EVs have since been found to play a role in development, as well as in diseases including cancers. To elucidate the roles of EVs, researchers have established different methods to visualize and study their spatiotemporal properties. However, since EV are nanometer-sized, imaging them demands a full understanding of each labeling strategy to ensure accurate monitoring. This review covers current and emerging strategies for EV imaging for prospective studies. BACKGROUND Extracellular vesicles (EVs) are heterogeneous nanoparticles released by cells. They were once considered as cellular wastes until studies revealed that EV serves as a means of cell-to-cell communication by shuttling DNAs, RNAs, proteins and lipids to neighboring and distant sites [1, 2]. Since then, EVs have been actively investigated under (patho)physiological settings, as well as for therapeutic development. To aid in these studies, many methods have been developed to label and characterize the spatiotemporal property of EVs. As each imaging strategy carries its advantages and disadvantages, this review aims to cover current and emerging methods, thereby facilitating choice for EV imaging in prospective studies. EXTRACELLULAR VESICLES Valadi et al. identified that EVs from human and mouse mast cell carry mRNAs and microRNAs (miRNAs) named “exosomal shuttle RNAs”, which could be delivered into recipient cells via EV uptake for translation [3]. Soon thereafter, Al-Nedawi et al. found EVs derived from gliomas could deliver an oncogenic form of EGFR (epidermal growth factor receptor), EGFRvIII [4], and further showed that EVs released by A431, A549 and DLD1 cancer cell lines could transfer EGFR to induce angiogenesis in human umbilical vein endothelial cells (HUVECs) [5]. Moreover, Ratajczak et al. discovered that EVs from embryonic stem cell (ES) could deliver mRNAs related to pluripotent transcription factors and Wnt-3 protein to murine hematopoietic progenitor cells (HPC) to enhance survival and expansion [6]. Since EVs could transport bioactive cargos between cells, EVs are recognized as important carriers to modulate phenotype and function of EV recipient cells [7]. While there are different EV subtypes based to their size, biogenesis and shape (Fig. 1), the collective term “EVs” is used in the current review unless otherwise specified.Fig. 1Schematic of different EV subpopulations. Different EV subtypes have different sizes and secretion pathways. Exosomes are generated from MVBs, and can carry protein and mRNAs cargo for cell-cell communication. Based on their sizes, exosomes can further characterized to small exosomes and large exosomes. Exomeres are nanoparticles with size smaller than 50 nm and carrying proteins involving metabolism; their biological role remains unknown. Microvesicles shed from the cell surface are generally larger than exosomes, and can also ferry cargos between cells. Oncosomes are larger EVs that were generated from cancer cells by budding or membrane scission, and can deliver cancer metastasis-related cargo to facilitate tumor cell invasion. Migrasomes are generated after cells migration with its function yet to be identified Exosomes are nanosized vesicles (30–100 nm) generated by the release of intraluminal vesicles following the fusion of multivesicular bodies (MVBs) with the plasma membrane. Cells first generate early endosomes by endocytosis [8–10]. During their maturation to late endosomes, some endosomes shed intraluminal vesicles (ILVs) within itself to become MVBs, which then migrate to the cell membrane [11]. Once fused with the plasma membrane, the MVBs release the vesicles within to the extracellular milieu as exosomes [12]. Since exosomes are generated from the MVBs, exosomes contain biomarkers such as Alix and tumor susceptibility gene 101 (Tsg101) which relate to ILV formation in endosomal sorting complex required for transport (ESCRT) [13]. Exosomes from dendritic cells, HeLa cells, human embryonic kidney cells 293 T (HEK293T) and retinal pigmented epithelial cells (RPE-1) were discovered to have tetraspanins like CD9, CD81 and CD63 which relate to endosomal vesicle trafficking [14, 15]. Therefore, these tetraspanins are also considered as common exosomal markers. Zhang et al. identified two kind of subpopulations of exosomes: large exosomes (Exo-L, 90–120 nm) and small exosomes (Exo-S, 60–80 nm) by asymmetric flow field-flow fraction (AF4) [16]. Using transmission electron microscopy (TEM) and mass spectrometry (MS) analysis, Exo-S/L were confirmed as encapsulated particles [15]. While both Exo-S/L exhibited similar biomarkers as exosomes including tetraspanins (CD9, CD63, CD81), Exo-S contained canonical exosomal proteins relating to ILVs, phagocytic vesicles, MVB and vacuoles like flotillin 1, flotillin 2, tweety family member 3, tetraspanin 14 and ESCRT-I subunit VPS37B. By contrast, Exo-L carried non-canonical proteins associated with membrane budding, late-endosome and trans-Golgi network such as annexin A1/A4/A5, charged multivesicular body protein 1A/2A/4B/5, vacuolar protein sorting 4 homologue B, heat shock protein family (Hsp40) member A1 and myosin IC. Furthermore, Zhang et al. identified a smaller, non-membranous nanoparticle named “exomere” (< 50 nm), which lacks the lipid bilayer of other EV subtypes [15]. Exomeres are enriched with proteins involved in metabolism including glycolysis and mTORC1 metabolic pathway [15], and its biological role remains to be elucidated in upcoming investigations. Microvesicles (100–1000 nm) are shed from the surface of cells which are generally larger than exosomes. The outward budding is related to the interaction of TSG101 with arrestin domain-containing protein 1 (ARRDC1). After binding with ARRDC1, TSG101 relocates from endosomes to the plasma membrane and facilitate MV release through Gag-mediated budding [17, 18]. MVs share some of the biomarkers with exosomes like CD63 [19], and both MVs and exosomes are known to transport bioactive cargos between cells [6]. Oncosomes or large oncosomes are large EVs released by cancer cells (1000–10,000 nm). They could be released like microvesicles by vesicle budding and membrane scission [20, 21] Oncosomes are frequently found in highly aggressive cancer cells as non-apoptotic plasma membrane blebs during amoeboid mode of cancer invasion [22]. Wolf et al. discovered that amoeboid-like tumor cells continuously expand and retract oncosomes around cell surface when tumor cells go through 3D collagen matrix [22]. Clancy et al. found the release of oncosomes from amoeboid-like invasive tumor cell, which is facilitated by soluble N-ethylmaleimide-sensitive-factor attachment protein receptor (SNARE) protein and vesicle-associated membrane protein (VAMP) with cargo delivery of membrane-type 1 matrix metalloprotease (MT1-MMP) [21, 23, 24]. Since MT1-MMP is a facilitator of tumor cell invasion and extracellular matrix (ECM) proteolysis [25, 26], oncosomes are suggested to play an important role in tumor cell invasion. Migrasomes (up to 3000 nm) are oval shaped microvesicles containing small vesicles formed during cell migration. Liang et al. discovered that cells secrete migrasomes from tips of their retraction fibers, which the authors described as pomegranate-like structures (PLS) [27]. PLS were found to express tetraspanin-4 (TSPAN4) as a PLS marker [27]. With time-lapse fluorescence imaging of TSPAN4-green fluorescent protein (GFP)-expressing normal rat kidney (NRK) cells, the authors found migrasome release was migration-dependent [27]. Yet, migrasome function remains to be elucidated. Although EV subtypes have different routes of biogenesis, biomarkers and sizes, their respective biological roles remain to be fully characterized. With the recent advances in EV labeling and imaging technologies, a more comprehensive understanding on the properties of EV subtypes

Read the complete text